Executive Summary: Evidence-Based Best Practice Guideline for Adult Patients with Severe-to-Profound Unilateral Sensorineural Hearing Loss

2015 ◽  
Vol 26 (07) ◽  
pp. 605-606 ◽  
Author(s):  
Michael Valente
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Practice Guideline ◽  
Best Practice ◽  
Sensorineural Hearing ◽  
Adult Patients ◽  
Evidence Based ◽  
Executive Summary

scholarly journals Prognostic factors for outcomes of idiopathic sudden sensorineural hearing loss: protocol for the SeaSHeL national prospective cohort study

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e038552
Author(s):  
Rishi Mandavia ◽  
Gerjon Hannink ◽  
Muhammad Nayeem Ahmed ◽  
Yaami Premakumar ◽  
Timothy Shun Man Chu ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Cohort Study ◽  
Sensorineural Hearing Loss ◽  
Prospective Cohort Study ◽  
Health Research ◽  
Prospective Cohort ◽  
Prognostic Model ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Adult Patients

IntroductionThe mainstay of treatment for idiopathic sudden sensorineural hearing loss (SSNHL) includes oral steroids, intratympanic steroid injections or a combination of both. The National Institute for Health and Care Excellence, in their recent hearing loss guidelines, highlighted the paucity of evidence assessing the comparative effectiveness of these treatments; and the National Institute for Health Research (NIHR) Health Technology Assessment Programme has since released a commissioned call for a trial to identify the most effective route of administration of steroids as a first-line treatment for idiopathic SSNHL. For such trials to be run effectively, reliable information is needed on patients with SSNHL: where they present, numbers, demographics, treatment pathways, as well as outcomes. This study will collect these data in a nationwide cohort study of patients presenting with SSNHL across 97 National Health Service (NHS) trusts. The study will be delivered through ear, nose and throat (ENT) trainee networks, the NIHR Clinical Research Network (CRN) Audiology Champions and the NIHR CRN. Importantly, this study will also provide a dataset to develop a prognostic model to predict recovery for patients with idiopathic SSNHL. The study objectives are to: (1) map the patient pathway and identify the characteristics of adult patients presenting to NHS ENT and hearing services with SSNHL, (2) develop a prognostic model to predict recovery for patients with idiopathic SSNHL and (3) establish the impact of idiopathic SSNHL on patients’ quality of life (QoL).Methods and analysisStudy design: national multicentre prospective cohort study across 97 NHS trusts.Inclusion criteria: adult patients presenting to NHS ENT and hearing services with SSNHL.Outcomes: change in auditory function; change in QoL score.Analysis: multivariable prognostic model, using prespecified candidate predictors. Mean change in QoL scores will be calculated from initial presentation to follow-up.Ethics and disseminationHealth Research Authority and NHS Research Ethics Committee approved the study. Publication will be on behalf of study sites and collaborators.Trial registration numberClinicalTrials.gov Registry (NCT04108598).

scholarly journals Metabolic Syndrome as a Risk Factor for Sensorineural Hearing Loss in Adult Patients with Turner Syndrome

2020 ◽  
Vol Volume 13 ◽  
pp. 25-35
Author(s):  
Francisco Álvarez-Nava ◽  
Marcia Racines-Orbe ◽  
Julia Witt ◽  
Jessica Guarderas ◽  
Yosselin Vicuña ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Hearing Loss ◽  
Risk Factor ◽  
Sensorineural Hearing Loss ◽  
Turner Syndrome ◽  
Sensorineural Hearing ◽  
Adult Patients

scholarly journals Effect of Antioxidant Vitamins as Adjuvant Therapy for Sudden Sensorineural Hearing Loss: Systematic Review Study

2018 ◽  
Vol 23 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Iman Ibrahim ◽  
Anthony Zeitouni ◽  
Sabrina Daniela da Silva
Keyword(s):  
Hearing Loss ◽  
Adjuvant Therapy ◽  
Sensorineural Hearing Loss ◽  
Conventional Treatment ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Antioxidant Vitamins ◽  
Adult Patients ◽  
Unknown Etiology ◽  
Control Group

Importance: Sudden sensorineural hearing loss (SSNHL) is an otological emergency of unknown etiology. Recent reports showed that antioxidant drugs can benefit patients with SSNHL. This study attempted to evaluate the effect of adding antioxidant vitamins as an adjuvant therapy alongside with corticosteroids. Objective: To evaluate the effects of the 3 major antioxidant vitamins (A, C, and E) as an adjuvant therapy, administered with corticosteroids, for the treatment of SSNHL in adult patients (≥18 years). Data Sources: MEDLINE, EMBASE, PubMed, Web of Science and Cochrane electronic databases from January 1, 1995, through September 25, 2017. Study Selection: Published studies of adult patients who received antioxidant vitamins (A, C, E, or any combination of these vitamins) as an adjuvant therapy in addition to the regular treatment (corticosteroids) for SSNHL. Quality assessment was performed using the Cochrane Collaboration Tool for Assessing Risk of Bias. Data Extraction: Each study had a control group (conventional treatment + placebo) and a trial group (antioxidant vitamin(s) + conventional treatment). Results: From 446 manuscripts identified in the literature, 3 studies were included in the review with 279 patients. The most common vitamins used to treat SSNHL were the 3 major antioxidant vitamins A, C, and E, combined sometimes with other antioxidants such as selenium. Conclusions and Relevance: The success of the treatment is increased in patients who received antioxidant vitamins in combination with conventional therapy.

scholarly journals Clinical Practice Guideline: Ménière’s Disease Executive Summary

2020 ◽  
Vol 162 (4) ◽  
pp. 415-434 ◽  
Author(s):  
Gregory J. Basura ◽  
Meredith E. Adams ◽  
Ashkan Monfared ◽  
Seth R. Schwartz ◽  
Patrick J. Antonelli ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Clinical Practice ◽  
Sensorineural Hearing Loss ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Meniere’S Disease ◽  
Sensorineural Hearing ◽  
Ménière’S Disease ◽  
Ménière's Disease

Objective Ménière’s disease (MD) is a clinical condition defined by spontaneous vertigo attacks (each lasting 20 minutes to 12 hours) with documented low- to midfrequency sensorineural hearing loss in the affected ear before, during, or after one of the episodes of vertigo. It also presents with fluctuating aural symptoms (hearing loss, tinnitus, or ear fullness) in the affected ear. The underlying etiology of MD is not completely clear, yet it has been associated with inner ear fluid volume increases, culminating in episodic ear symptoms (vertigo, fluctuating hearing loss, tinnitus, and aural fullness). Physical examination findings are often unremarkable, and audiometric testing may or may not show low- to midfrequency sensorineural hearing loss. Imaging, if performed, is also typically normal. The goals of MD treatment are to prevent or reduce vertigo severity and frequency; relieve or prevent hearing loss, tinnitus, and aural fullness; and improve quality of life. Treatment approaches to MD are many, and approaches typically include modifications of lifestyle factors (eg, diet) and medical, surgical, or a combination of therapies. Purpose The primary purpose of this clinical practice guideline is to improve the quality of the diagnostic workup and treatment outcomes of MD. To achieve this purpose, the goals of this guideline are to use the best available published scientific and/or clinical evidence to enhance diagnostic accuracy and appropriate therapeutic interventions (medical and surgical) while reducing unindicated diagnostic testing and/or imaging.

Sign in / Sign up

Export Citation Format

Share Document